Colorectal cancer chemoresistance continues to be a major obstacle for clinicians treating advanced malignancies. Recent research published in Advanced Science identifies the transcription factor POU2F1 as a critical driver of this resistance. The study demonstrates that POU2F1 is significantly overexpressed in chemotherapy-resistant colorectal cancer (CRC) cells. By manipulating metabolic pathways, this oncogene prevents the degradation of proteins that help cancer cells survive treatment. These findings provide a novel understanding of how metabolic reprogramming influences therapeutic outcomes.

The core of this resistance mechanism involves the regulation of lactate export. Specifically, POU2F1 stimulates the expression of MCT4, a protein responsible for transporting lactate out of the cell. This increased export leads to a decrease in cytosolic lactate levels. Consequently, the lactylation of PPP1R11 is significantly reduced. Under normal conditions, lactylation stabilizes PPP1R11 and enhances its E3 ligase activity. This activity is essential because it promotes the ubiquitination and subsequent degradation of MDR2, a multidrug resistance protein.

Mechanisms of Colorectal Cancer Chemoresistance

Furthermore, when POU2F1 suppresses the lactylation of PPP1R11, the MDR2 protein remains stable and active. MDR2 effectively pumps chemotherapeutic agents out of the cancer cells, thereby reducing their sensitivity to treatment. Therefore, the POU2F1/MCT4 axis represents a vital target for future therapeutic interventions. By inhibiting this pathway, researchers hope to restore the degradation of MDR2 and enhance the efficacy of standard chemotherapy. Moreover, this study broadens our understanding of how post-translational modifications like lactylation bridge the gap between metabolism and drug resistance.

In addition, these insights offer potential biomarkers for predicting treatment response in CRC patients. Monitoring POU2F1 and MCT4 levels could help oncologists identify patients who may require alternative or combination therapies. Thus, targeting the metabolic environment of the tumor remains a promising strategy for overcoming colorectal cancer chemoresistance.

Frequently Asked Questions

How does POU2F1 contribute to drug resistance?

POU2F1 promotes drug resistance by increasing the expression of the lactate transporter MCT4. This leads to reduced intracellular lactylation of PPP1R11, which prevents the degradation of the multidrug resistance protein MDR2.

What is the clinical significance of PPP1R11 lactylation?

Lactylation of PPP1R11 is a modification that stabilizes the protein and boosts its ability to degrade resistance-linked proteins. When lactylation is low, cancer cells can accumulate MDR2 and resist chemotherapy.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare guidance. Always consult with a qualified physician for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Xia L et al. POU2F1 Promotes Chemoresistance in Colorectal Cancer Cells via Attenuates the MDR2 Degradation Mediated by PPP1R11 Lactylation. Adv Sci (Weinh). 2026 Mar 07. doi: 10.1002/advs.202522316. PMID: 41793212.

Liu Y, et al. The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis. Cancer Metab. 2022;10(1):1.

Zhang N, et al. Lactylation in cancer: Advances and opportunities for treatment resistance. PMC. 2025;9(29).